durvalumab and oleclumab in patients with relapsed ovarian cancer
Published 2 years ago • 110 plays • Length 3:03Download video MP4
Download video MP3
Similar videos
-
1:07
combining 1l chemo-immunotherapy with oleclumab in patients with advanced tnbc
-
2:53
hudson: durvalumab combination therapies to overcome pd-l1 blockade resistance in advanced nsclc
-
1:22
dora: durvalumab and olaparib in platinum treated advanced tnbc
-
6:40
keynote-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
-
1:02
synergy: 1l chemo-immunotherapy with or without the anti-cd73 antibody oleclumab in advanced tnbc
-
2:27
avelumab in patients with relapsed or recurrent ovarian cancer
-
3:26
infinty: tremelimumab and durvalumab in msi-high gc/gejc
-
1:06
improving immunotherapy outcomes in ovarian cancer
-
3:47
gog-0218: which patients with ovarian cancer experience highest benefit from 1l bevacizumab?
-
2:53
oleclumab plus osimertinib for advanced egfrm nsclc
-
1:05
dr. sonpavde on the role of durvalumab in platinum-refractory bladder cancer
-
2:50
aurelia: phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
-
1:05
areas of unmet need for patients with ovarian cancer
-
5:25
durvalumab with olapirib shows no pfs improvement for platinum-ineligible bladder cancer
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
25:30
innovative and emerging trials in ovarian cancer
-
2:02
intravesical io using durvalumab shows promising results for patients with high-risk nmibc
-
2:55
highlights of durvalumab for advanced bladder cancer
-
36:41
what’s on the horizon for ovarian cancer diagnosis and treatment? – with professor charlie gourley